Advances in active and passive immunotherapy for Alzheimer’s disease – a short review
DOI:
https://doi.org/10.15584/medrev.2016.1.8Keywords:
Alzheimer’s disease, active immunotherapy, passive immunotherapyAbstract
Disease-modifying alternatives are intensively developed for the treatment of neurodegenerative disorders, a group of diseases that afflict millions of patients annually. The pre-clinical data shown involvement of immune system in the pathogenesis of Alzheimer’s disease (AD). Microglia cells, antigen presenting cells like dendritic cells and products of complement activation take an active part in neurodegeneration. On the other hand, some components of immune system could be used for elimination of amyloid plaques and another structural abnormalities associated with AD. Because of that, passive and active immunotherapies are one of the most developed approaches in therapy of AD. Vaccination against amyloid-ß, α-synuclein, or tau has been extensively explored, especially as the discovery that these proteins may propagate cell-to-cell and be accessible to antibodies when embedded into the plasma membrane or in the extracellular space. Also other methods of passive (intravenous immunoglobulins) and active (DNA based vaccines) are associated with positive clinical outcome. The clinical development of efficient and safe immunotherapies for Alzheimer ’s disease and other neurodegenerative disorders is a field in constant evolution.
Downloads
References
Jindal H, Bhatt B, Sk S, Singh Malik J. Alzheimer disease immunotherapeutics: then and now. Hum VaccinImmunother 2014;10(9):2741-3.
Heneka MT, Carson MJ, El Khoury J, et. al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol2015;14(4):388-405.
Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol 2015;16(3):229-36.
Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer’s disease. BiochemPharmacol 2014;88(4):594-604.
Fu HJ, Liu B, Frost JL, Lemere CA. Amyloid-beta immunotherapy for Alzheimer’s disease. CNS NeurolDisord Drug Targets 2010;9(2):197-206.
Valera E, Spencer B, Masliah E. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 2016;13(1):179-189.
Andreasen N, Simeoni M, Ostlund H, et. al. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer’s disease: a randomized, placebo-controlled study. PLoS One 2015;19;10(3):e0098153.
Leyhe T, Andreasen N, Simeoni M, et. al. Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study. Alzheimers Res Ther 2014;6(2):19.
Orgogozo JM, Gilman S, Dartigues JF, et. al. Subacute meningoencephalitisin a subset of patients with AD after Abeta42 immunization.Neurology 2003;61:46-54.
Farlow MR, Andreasen N, Riviere ME, et. al. Long-term Medical Review 2015; 14 (1): 93–96 treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease.Alzheimers Res Ther 2015;7(1):23.
Masliah E, Iwai A, Mallory M, Ueda K, Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer’s disease. Am J Pathol 1996;148:201-210.
Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PloS One 2013;8(8):e72301.
Relkin N. Intravenous immunoglobulin for Alzheimer’s disease. ClinExpImmunol 2014;178(1):74-79.
Klyubin I, Nicoll AJ, Khalili-Shirazi A, et. al. Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer’s disease Aβsynaptotoxicity. J Neurosci 2014;34(18):6140-6145.
Landlinger C, Oberleitner L, Gruber P, et. al. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer’s disease. J Neuroinflammation 2015;12:150.
Cheng J, Lin X, Morgan D, et. al. Dendritic and Langerhans cells respond to Aβ peptides differently: implication for AD immunotherapy. Oncotarget 2015;6(34):35443-35457.
Koronyo Y, Salumbides BC, Sheyn J, et. al. Therapeutic effects of glatiramer acetate and grafted CD115+monocytes in a mouse model of Alzheimer’s disease. Brain2015;138:2399-2422.
DiFrancesco JC, Longoni M, Piazza F. Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA):Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy. Front Neurol 2015;6:207.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Medical Review
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
